$AZN
Market Cap:
$AZN SEC Filings
| Filing | Filed On |
|---|---|
| PUBLICATION OF A PROSPECTUS | 12 Jun 2019 |
| CALQUENCE PHASE III ELEVATE-TN TRIAL MET PRIMARY | 06 Jun 2019 |
| LYNPARZA NEARLY DOUBLED THE TIME PATIENTS LIVED WITHOUT DISEASE PROGRESSION FROM | 03 Jun 2019 |
| TOTAL VOTING RIGHTS | 03 Jun 2019 |
| BLOCK LISTING INTERIM REVIEW | 03 Jun 2019 |
| POOLED ANALYSES OF THE ROXADUSTAT GLOBAL PHASE III | 10 May 2019 |
| DIRECTOR/PDMR SHAREHOLDING | 08 May 2019 |
| DIRECTOR DECLARATION | 08 May 2019 |
| TRASTUZUMAB DERUXTECAN DEMONSTRATED CLINICALLY | 08 May 2019 |
| CALQUENCE PHIII ASCEND TRIAL MET PRIMARY ENDPOINT | 07 May 2019 |
| QTERNMET XR APPROVED IN THE US FOR TYPE-2 DIABETES | 03 May 2019 |
| DIRECTOR/PDMR SHAREHOLDING | 01 May 2019 |
| TOTAL VOTING RIGHTS | 01 May 2019 |
| LYNPARZA RECEIVES POSITIVE EU CHMP OPINION FOR 1ST | 29 Apr 2019 |
| AZN: Q1 2019 RESULTS | 26 Apr 2019 |
| RESULT OF AGM | 26 Apr 2019 |
| LYNPARZA APPROVED IN EU FOR THE TREATMENT OF GERMLINE BRCA-MUTATED HER2-NEGATIVE | 10 Apr 2019 |
| HOLDING(S) IN COMPANY | 04 Apr 2019 |
| DIRECTOR/PDMR SHAREHOLDING | 03 Apr 2019 |
| TOTAL VOTING RIGHTS | 02 Apr 2019 |
